References
- The EuroQol Group. The EQ-5D-3L User Guide 2015. www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2015.pdf. Accessed 25 January 2016.
- Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care Res (Hoboken) 2010;62:1399–406.
- Burström K, Sun S, Gerdtham UG, Henriksson M, Johannesson M, Levin LÅ, et al. Swedish experience-based value sets for EQ-5D health states. Qual Life Res 2014;23:431–42.
- Little MH, Reitmeir P, Peters A, Leidl R. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups. Value Health 2014;17:364–71.
- Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden. Ann Rheum Dis 2010;69:352–7.
- Karlsson JA, Nilsson JA, Neovius M, Kristensen L-E, Gulfe A, Saxne T, et al. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients. Ann Rheum Dis 2011;70:2163–6.
- Khanna D, Tsevat J. Health-related quality of life–an introduction. Am J Manag Care 2007;13:S218–23.
- Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol 2007;34:1188–93.
- Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;6:793–8.
- Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1159–61.
- Gulfe A, Kristensen LE, Geborek P. Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009;36:517–21.
- Kvamme MK, Kristiansen IS, Lie E, Kvien TK. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2010;37:26–31.
- Paulsen A, Roos EM, Pedersen AB, Overgaard S. Minimal clinically important improvement (MCII) and patient-acceptable symptom state (PASS) in total hip arthroplasty (THA) patients 1 year postoperatively. Acta Orthop 2014;85:39–48.
- Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IM, Novaes GS. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004;31:1293–6.
- Studenic P, Radner H, Smolen JS, Aletaha D. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 2012;64: 2814–23.
- The EuroQoL Group. EQ-5D-3L User Gudie 2015. (www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGudie_2015.pdf). Accessed 23 February 2016.